Skip to main navigation
  • Newsroom
  • Get in Touch
  • LinkedIn
Editas Medicine logo
  • Research and Pipeline
  • CRISPR Gene Editing
  • For Patients
  • Who We Are
  • Join Our Team
  • Investors
  • Newsroom
  • Get in Touch
  • LinkedIn

Media & Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
    • Annual Meeting Materials
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
  • Investor FAQs
  • Contact

Press Releases

Press Releases

Keyword Search

February 15, 2023
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
January 19, 2023
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
January 9, 2023
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
January 4, 2023
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2

>> Main navigation

  • Research and Pipeline
  • CRISPR Gene Editing
  • For Patients
  • Who We Are
  • Join Our Team
  • Investors

©Copyright 2023 Editas Medicine

>> Footer menu

  • Get in Touch
  • Investors
  • Privacy Policy
  • Terms of Use